Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (SE:STABL)
:STABL
STABL Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.22 - kr1.05
Previous CloseN/A
Volume514.07K
Average Volume (3M)561.36K
Market Cap
kr23.79M
Enterprise ValueN/A
Total Cash (Recent Filing)kr2.19M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding51,720,900
10 Day Avg. Volume148,210
30 Day Avg. Volume561,357
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
STABL FAQ
What was Stayble Therapeutics AB’s price range in the past 12 months?
Stayble Therapeutics AB lowest stock price was kr0.22 and its highest was kr1.05 in the past 12 months.
What is Stayble Therapeutics AB’s market cap?
Stayble Therapeutics AB’s market cap is kr23.79M.
When is Stayble Therapeutics AB’s upcoming earnings report date?
Stayble Therapeutics AB’s upcoming earnings report date is May 20, 2025 which is in 24 days.
How were Stayble Therapeutics AB’s earnings last quarter?
Stayble Therapeutics AB released its earnings results on Feb 25, 2025. The company reported -kr0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.069.
Is Stayble Therapeutics AB overvalued?
According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued.
Does Stayble Therapeutics AB pay dividends?
Stayble Therapeutics AB does not currently pay dividends.
What is Stayble Therapeutics AB’s EPS estimate?
Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stayble Therapeutics AB have?
Stayble Therapeutics AB has 51,720,900 shares outstanding.
What happened to Stayble Therapeutics AB’s price movement after its last earnings report?
Stayble Therapeutics AB reported an EPS of -kr0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Stayble Therapeutics AB?
Currently, no hedge funds are holding shares in SE:STABL
---
Company Description
Stayble Therapeutics AB
Stayble Therapeutics AB is a clinical stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
---
Technical Analysis
Diagonal Bio AB
―
LIDDS AB
―
Lipigon Pharmaceuticals AB
―
CombiGene AB
―
QuiaPEG Pharmaceuticals Holding AB
―
---